PCL, Inc. (KOSDAQ:241820)
South Korea · Delayed Price · Currency is KRW 302.00
-5.00 (-1.63%)
Mar 21, 2025, 5:32 PM KST
PCL, Inc. Revenue
PCL, Inc. had revenue of 1.68B KRW in the quarter ending June 30, 2025, with 385.18% growth. This brings the company's revenue in the last twelve months to 4.16B, down -46.90% year-over-year. In the year 2024, PCL, Inc. had annual revenue of 1.25B, down -85.22%.
Revenue (ttm)
4.16B
Revenue Growth
-46.90%
P/S Ratio
4.30
Revenue / Employee
134.11M
Employees
31
Market Cap
17.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.25B | -7.18B | -85.22% |
| Dec 31, 2023 | 8.43B | -28.79B | -77.35% |
| Dec 31, 2022 | 37.22B | -8.93B | -19.35% |
| Dec 31, 2021 | 46.15B | -7.54B | -14.04% |
| Dec 31, 2020 | 53.68B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| SK Biopharmaceuticals | 620.28B |
| Yuhan | 2,165.44B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |